Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. by Deborah Charych, Samira Khalili, Vidula Dixit, Peter Kirk, Thomas Chang, John Langowski, Werner Rubas, Stephen K Doberstein, Michael Eldon, Ute Hoch, Jonathan Zalevsky

Get full text

NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer by William L Redmond, Ute Hoch, Melissa J Kasiewicz, Michael J McNamara, Deborah H Charych, Joshua M Walker, Annah S Rolig, Daniel C Rose, Ian F Hilgart-Martiszus

Get full text

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study by Mario Sznol, Adi Diab, Jonathan Zalevsky, Ute Hoch, Mehmet A Bilen, Giovanni Grignani, Nizar M Tannir, Erika Puente, Arjun V Balar, Daniel C Cho, Arlene O Siefker-Radtke, Lily Tang, David Chien, Arkopal Choudhury, Danni Yu, Sue L Currie, Mary A Tagliaferri, Michael E Hurwitz

Get full text

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy by Meenu Sharma, Hiep Khong, Faisal Fa’ak, Salah-Eddine Bentebibel, Louise M. E. Janssen, Brent C. Chesson, Caitlin A. Creasy, Marie-Andrée Forget, Laura Maria S. Kahn, Barbara Pazdrak, Binisha Karki, Yared Hailemichael, Manisha Singh, Christina Vianden, Srinivas Vennam, Uddalak Bharadwaj, David J. Tweardy, Cara Haymaker, Chantale Bernatchez, Shixia Huang, Kimal Rajapakshe, Cristian Coarfa, Michael E. Hurwitz, Mario Sznol, Patrick Hwu, Ute Hoch, Murali Addepalli, Deborah H. Charych, Jonathan Zalevsky, Adi Diab, Willem W. Overwijk

Get full text